Wire · opportunities
Roche's phase 3 win tees up fight with Novartis for blockbuster kidney disease market
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 September 2026 · Fusion42 review
Roche reported a positive phase 3 interim analysis for sefaxersen in IgA nephropathy, showing significant proteinuria reduction, positioning the drug for accelerated approval talks and setting up a competitive market challenge against Novartis' Fabhalta.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 23 Sep 2026 and 25 Sep 2026.
◆ ◆ The Wire takeaway
You need to prepare for a regulatory push in kidney disease drugs as Roche’s sefaxersen nears accelerated approval, opening a window against Novartis’ oral Fabhalta. Align development and market strategies now to capitalise on the shifting competitive and treatment modality balance.
◆ Coverage
3 sources · first reported 23 Sep 2026 · latest 25 Sep 2026
◆ Related on Wire
◆ Topics